

Fax completed form to: (855) 840-1678
If this is an URGENT request, please call (800) 882-4462 (800.88.CIGNA)

## Tremfya IV (guselkumab)

PHYSICIAN INFORMATION			PATIENT INFORMATION				
* Physician Name:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this				
Specialty:	* DEA	NPI or TIN:	form are completed.*				
Office Contact Person:			* Patient Name:				
Office Phone:			* Cigna ID: * Date of Birth:				
Office Fax:			* Patient Street Address:				
Office Street Address:			City:	Stat	e:	Zip:	
City:	State:	Zip:	Patient Phone:				
Urgency:							
☐ Standard		ing this box, I attest to the fact that copardize the customer's life, health					
Medication requested: ☐ Tremfya IV							
ICD10:							
Directions for use:		Dose and Quantity	y: Duration of therapy:				
Where will this medicat  Accredo Specialty Pharn Hospital Outpatient Prescriber's office stock Other (please specify):  **Medication orders can be NCPDP 4436920), Fax 888.	☐ Retail pharmacy ☐ Home Health / Home Infusion vendor **Cigna's nationally preferred specialty pharmacy - Accredo (1620 Century Center Pkwy, Memphis, TN 38134-8822						
Facility and/or doctor dispensing and administering medication:							
Facility Name: Address (City, State, Zip Code):		State:	Тах	Tax ID#:			
Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient?							
Diagnosis related to use Crohn's disease Ulcerative colitis All other indications or di							
Clinical Information:							
Will the requested medication be administered in combination with a BIOLOGIC or in combination with a targeted synthetic oral small molecule drug?  Biologic (an adalimumab product [Humira, biosimilar], Bimzelx, Cosentyx (IV or SC), etanercept SC product [Enbrel, biosimilar], Entyvio (IV or SC), Ilumya, infliximab IV products [Remicade, biosimilar], Kevzara, Kineret, Omvoh (IV or SC), Orencia [IV or SC], a rituximab IV product [Rituxan, biosimilar], Skyrizi (IV or SC), Siliq, Simponi [Aria or SC]), an ustekinumab product [Stelara (IV or SC), biosimilar], Taltz, a tocilizumab product [Actemra (IV or SC), biosimilar], Tremfya (IV or SC), or Zymfentra  Targeted synthetic oral small molecule drug (such as Cibinqo, Leqselvi, Litfulo, Sotyktu, Olumiant, Otezla, Rinvoq, Rinvoq LQ, Xeljanz, Xeljanz XR, Velsipity, or Zeposia.)  Conventional synthetic DMARD (such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine)  No, the requested medication will NOT be used in combination with another BIOLOGIC or targeted synthetic oral small molecule drug.							

Save Time! Submit Online at: <a href="https://www.covermymeds.com/main/prior-authorization-forms/cigna/">www.covermymeds.com/main/prior-authorization-forms/cigna/</a> or via SureScripts in your EHR.							
information reported on this form.  Prescriber Signature:	Date:						
Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form							
Additional Pertinent Information: Please provide any additional pertinent clinical information on the requested drug (with dates of use) and how they have been receiving it (for example: sample) sample.							
Is this medication being prescribed by or in consultation with a gastroenterologist?	☐ Yes ☐ No						
Will the requested medication be used as induction therapy?	☐ Yes ☐ No						
(if no) Does the patient have enterocutaneous (perianal or abd (if no) Has the patient had an ileocolonic resection (to disease recurrence)?	☐ Yes ☐ No						
(if no) Has the patient had a previous trial of one biologic for Crohn's disease other than the drug? Please Note: A biosimilar of the requested biologic does not count. Examples of biol Cimzia, Entyvio, an infliximab IV product (Remicade, biosimilars), an adalimumab product biosimilars), Omvoh (IV or SC), Skyrizi (IV or SC), an ustekinumab product [Stelara (IV or SZ), Symfentra.							
(if no) Has the patient tried one other conventional systemic therapy for Crohn's disease? Please Note: Examp systemic therapies for Crohn's disease include azathioprine, 6-mercaptopurine, and methotrexate. A trial of mesalamine does not count as a systemic agent for Crohn's disease.							
(if no) Is a systemic corticosteroid contraindicated in this patient?	☐ Yes ☐ No						
(if CD) Has the patient tried a systemic corticosteroid or is currently taking a systemic corticosteroid	d? ☐ Yes ☐ No						
(if no biologic for UC) Has the patient tried an antibiotic, probiotic, corticosteroid en Please Note: Examples of antibiotics include metronidazole and ciprofloxacin. Ex include hydrocortisone enema.							
(if no) Does the patient have pouchitis?	gic does not count.  Yes No Yes No						
(if no) Has the patient had a trial of a biologic for ulcerative colitis? Please Note: Examples include an adalimumab product (Humira, biosimilars), Entyvio (IV or SC), an infliximab IV product (Remicade, biosimilars), Omvoh, Zymfentra, Simponi SC, Skyrizi, or an ustekinumab product [Stelara (IV or SC)]. A biosimilar of the requested biologic does not count.							
(if UC) Has the patient had a trial of one systemic therapy for ulcerative colitis? Please Note: Examples include 6-mercaptopurine, azathioprine, cyclosporine, tacrolimus, or a corticosteroid such as prednisone, methylprednisolone. A trial of a mesalamine product does not count as a systemic therapy for ulcerative colitis.							

Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.

v051525